How can the mood stabilizer VPA limit both mania and depression?

Molecular and Cellular Neuroscience

Volumn 29, Issue 2, 2005, Pages 155-161

  Cheng, Lili ^a   Lumb, Michael ^a   Polgár, László ^b   Mudge, Anne W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b INSTITUTE OF ENZYMOLOGY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; DESIPRAMINE; FLUOXETINE; LITHIUM; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; PHOSPHATIDYLINOSITIDE; PROLYL ENDOPEPTIDASE; RECOMBINANT PROLYL ENDOPEPTIDASE; UNCLASSIFIED DRUG; VALPROIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; ENZYME INHIBITION; HUMAN; MANIA; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANIMALS, NEWBORN; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; BRAIN CHEMISTRY; CELLS, CULTURED; DOWN-REGULATION; HUMANS; MODELS, NEUROLOGICAL; NEURONS; PHOSPHATIDYLINOSITOLS; RATS; RECOMBINANT FUSION PROTEINS; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; UP-REGULATION; VALPROIC ACID;

EID: 19444377984     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2004.12.003     Document Type: Article

References (44)

1. G. Agam, A. Shamir, G. Shaltiel, and M.L. Greenberg Myo-inositol-1- phosphate (MIP) synthase: a possible new target for antibipolar drugs Bipolar Disord. 4 Suppl. 1 2002 15 20
2. A.I. Barkai, D.L. Dunner, H.A. Gross, P. Mayo, and R.R. Fieve Reduced myo-inositol levels in cerebrospinal fluid from patients with affective disorder Biol. Psychiatry 13 1978 65 72
3. M.J. Berridge, C.P. Downes, and M.R. Hanley Neural and developmental actions of lithium: a unifying hypothesis Cell 59 1989 411 419
4. N. Brose, and C. Rosenmund Move over protein kinase C, you've got company: alternative cellular effectors of diacylglycerol and phorbol esters J. Cell Sci. 115 2002 4399 4411
5. J.R. Calabrese, M.D. Shelton, D.J. Rapport, S.E. Kimmel, and O. Elhaj Long-term treatment of bipolar disorder with lamotrigine J. Clin. Psychiatry 63 Suppl. 10 2002 18 22
6. L. Cheng, and A.W. Mudge Cultured Schwann cells constitutively express the myelin protein P0 Neuron 16 1996 309 319
7. K.N. Chengappa, J. Levine, S. Gershon, A.G. Mallinger, A. Hardan, A. Vagnucci, B. Pollock, J. Luther, J. Buttenfield, S. Verfaille, and D.J. Kupfer Inositol as an add-on treatment for bipolar depression Bipolar Disord. 2 2000 47 55
8. J.T. Coyle, and R.S. Duman Finding the intracellular signaling pathways affected by mood disorder treatments Neuron 38 2003 157 160
9. P. Davanzo, M.A. Thomas, K. Yue, T. Oshiro, T. Belin, M. Strober, and J. McCracken Decreased anterior cingulate myo-inositol/creatine spectroscopy resonance with lithium treatment in children with bipolar disorder Neuropsychopharmacology 24 2001 359 369
10. P. Delmas, M. Crest, and D.A. Brown Functional organization of PLC signaling microdomains in neurons Trends Neurosci. 27 2004 41 47
11. H. Einat, and R.H. Belmaker The effects of inositol treatment in animal models of psychiatric disorders J. Affect Disord. 62 2001 113 121
12. H. Einat, H. Karbovski, J. Korik, D. Tsalah, and R.H. Belmaker Inositol reduces depressive-like behaviors in two different animal models of depression Psychopharmacology (Berlin) 144 1999 158 162
13. R. Frey, D. Metzler, P. Fischer, A. Heiden, J. Scharfetter, E. Moser, and S. Kasper Myo-inositol in depressive and healthy subjects determined by frontal 1H-magnetic resonance spectroscopy at 1.5 Tesla J. Psychiatry Res. 32 1998 411 420
14. V. Fulop, Z. Bocskei, and L. Polgar Prolyl oligopeptidase: an unusual beta-propeller domain regulates proteolysis Cell 94 1998 161 170
15. G.M. Goodwin Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology J. Psychopharmacol. 17 2003 149 173 (discussion 147)
16. T.D. Gould, J.A. Quiroz, J. Singh, C.A. Zarate, and H.K. Manji Emerging experimental therapeutics for bipolar disorder: insights from the molecular and cellular actions of current mood stabilizers Mol. Psychiatry 9 2004 734 755
17. N. Gurvich, and P.S. Klein Lithium and valproic acid: parallels and contrasts in diverse signaling contexts Pharmacol. Ther. 96 2002 45 66
18. A.J. Harwood, and G. Agam Search for a common mechanism of mood stabilizers Biochem. Pharmacol. 66 2003 179 189
19. J. Irazusta, G. Larrinaga, J. Gonzalez-Maeso, J. Gil, J.J. Meana, and L. Casis Distribution of prolyl endopeptidase activities in rat and human brain Neurochem. Int. 40 2002 337 345
20. S. Ju, G. Shaltiel, A. Shamir, G. Agam, and M.L. Greenberg Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast J. Biol. Chem. 279 2004 21759 21765
21. T. Juhasz, Z. Szeltner, V. Renner, and L. Polgar Role of the oxyanion binding site and subsites S1 and S2 in the catalysis of oligopeptidase B, a novel target for antimicrobial chemotherapy Biochemistry 41 2002 4096 4106
22. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. U. S. A. 93 1996 8455 8459
23. J. Levine, Y. Barak, M. Gonzalves, H. Szor, A. Elizur, O. Kofman, and R.H. Belmaker Double-blind, controlled trial of inositol treatment of depression Am. J. Psychiatry 152 1995 792 794
24. B.E. Lonze, and D.D. Ginty Function and regulation of CREB family transcription factors in the nervous system Neuron 35 2002 605 623
25. M. Maes, F. Goossens, S. Scharpe, J. Calabrese, R. Desnyder, and H.Y. Meltzer Alterations in plasma prolyl endopeptidase activity in depression, mania, and schizophrenia: effects of antidepressants, mood stabilizers, and antipsychotic drugs Psychiatry Res. 58 1995 217 225
26. M. Maes, F. Goossens, A. Lin, I. De Meester, A. Van Gastel, and S. Scharpe Effects of psychological stress on serum prolyl endopeptidase and dipeptidyl peptidase IV activity in humans: higher serum prolyl endopeptidase activity is related to stress-induced anxiety Psychoneuroendocrinology 23 1998 485 495
27. P. Morain, J.L. Robin, G. De Nanteuil, R. Jochemsen, V. Heidet, and D. Guez Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study Br. J. Clin. Pharmacol. 50 2000 350 359
28. T. Nagase, K.I. Ito, K. Kato, K. Kaneko, K. Kohda, M. Matsumoto, A. Hoshino, T. Inoue, S. Fujii, H. Kato, and K. Mikoshiba Long-term potentiation and long-term depression in hippocampal CA1 neurons of mice lacking the IP(3) type 1 receptor Neuroscience 117 2003 821 830
29. G. Nagy, K. Reim, U. Matti, N. Brose, T. Binz, J. Rettig, E. Neher, and J.B. Sorensen Regulation of releasable vesicle pool sizes by protein kinase A-dependent phosphorylation of SNAP-25 Neuron 41 2004 417 429
30. S.R. Nahorski, K.W. Young, R.A. John Challiss, and M.S. Nash Visualizing phosphoinositide signalling in single neurons gets a green light Trends Neurosci. 26 2003 444 452
31. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold, and L.M. Monteggia Neurobiology of depression Neuron 34 2002 13 25
32. M. Nishiyama, A. Hoshino, L. Tsai, J.R. Henley, Y. Goshima, M. Tessier-Lavigne, M.M. Poo, and K. Hong Cyclic AMP/GMP-dependent modulation of Ca2+ channels sets the polarity of nerve growth-cone turning Nature 424 2003 990 995
33. T. O'Donnell, S. Rotzinger, T.T. Nakashima, C.C. Hanstock, M. Ulrich, and P.H. Silverstone Chronic lithium and sodium valproate both decrease the concentration of myo-inositol and increase the concentration of inositol monophosphates in rat brain Brain Res. 880 2000 84 91
34. R.M. O'Leary, S.P. Gallagher, and B. O'Connor Purification and characterization of a novel membrane-bound form of prolyl endopeptidase from bovine brain Int. J. Biochem. Cell Biol. 28 1996 441 449
35. C.J. Phiel, F. Zhang, E.Y. Huang, M.G. Guenther, M.A. Lazar, and P.S. Klein Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen J. Biol. Chem. 276 2001 36734 36741
36. L. Polgar The prolyl oligopeptidase family Cell Mol. Life Sci. 59 2002 349 362
37. I. Schulz, B. Gerhartz, A. Neubauer, A. Holloschi, U. Heiser, M. Hafner, and H.U. Demuth Modulation of inositol 1,4,5-triphosphate concentration by prolyl endopeptidase inhibition Eur. J. Biochem. 269 2002 5813 5820
38. H. Shimon, G. Agam, R.H. Belmaker, T.M. Hyde, and J.E. Kleinman Reduced frontal cortex inositol levels in postmortem brain of suicide victims and patients with bipolar disorder Am. J. Psychiatry 154 1997 1148 1150
39. P.H. Silverstone, R.H. Wu, T. O'Donnell, M. Ulrich, S.J. Asghar, and C.C. Hanstock Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients Hum. Psychopharmacol. 17 2002 321 327
40. Z. Szeltner, V. Renner, and L. Polgar Substrate- and pH-dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family Protein Sci. 9 2000 353 360
41. D. Taylor, D. McConnell, H. McConnell, and R. Kerwin The South London and Maudsley NHS Trust 2001 Prescribing Guidelines 6th ed. 2001 Martin Dunitz, Publ.
42. D. van Calker, and R.H. Belmaker The high affinity inositol transport system-implications for the pathophysiology and treatment of bipolar disorder Bipolar Disord. 2 2000 102 107
43. R.S. Williams, M. Eames, W.J. Ryves, J. Viggars, and A.J. Harwood Loss of a prolyl oligopeptidase confers resistance to lithium by elevation of inositol (1,4,5) trisphosphate EMBO J. 18 1999 2734 2745
44. R.S. Williams, L. Cheng, A.W. Mudge, and A.J. Harwood A common mechanism of action for three mood-stabilizing drugs Nature 417 2002 292 295 (Mudge, A.W. and Harwood, A.J. contributed equally to this work)